David Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).
David Planchard, MD, PhD
Advertisement
David Planchard is a thoracic oncologist and head of the thoracic pathology committee at Gustave Roussy. He is also president of the International Center for Thoracic Cancers (CICT), a health cooperation group combining Gustave Roussy, the Marie-Lannelongue Hospital, and the Paris Saint-Joseph Hospital.
Articles by David Planchard, MD, PhD
Advertisement
Latest Updated Articles
Standard of Care for EGFR+ ES-NSCLCOctober 20th 2020
Practical Implications of ADAURA in NSCLCOctober 20th 2020
Molecular Testing in Early-Stage NSCLCOctober 20th 2020
Testing for EGFR in NSCLC WorldwideOctober 20th 2020
Adjuvant Approaches in EGFR+ NSCLCOctober 20th 2020
Clinical Evaluation of ES-NSCLC in JapanOctober 20th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
3
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
4
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
5